More Life. Less Pain. Cancer Rx Delivers Both.
Zytiga ( abiraterone acetate) received expanded use approval to treat men with advanced prostate cancer last week. In addition to extending lives, a new study has found Zytiga also keeps men feeling better during their journey.
Advanced Prostate Cancer Rx Being Reviewed
Men with metastatic prostate cancer may have a new treatment. Radium-223 dichloride (radium-223) is designed to treat castration-resistant prostate cancer that has spread to the bone.
Drug May Reduce Cancer Spread to Bone
Patients with advanced prostate cancer may have cancer cells that spread to the bone and cause pain. A new drug shows promise by rapidly reducing prostate cancer bone tumors.
New Option For Late-Stage Prostate Cancer
Men with castration-resistant prostate cancer have another treatment option. The US Food and Drug Administration (FDA) has approved the expanded use of Zytiga (abiraterone acetate).
FDA Expands Zytiga’s use for Late-Stage Prostate Cancer
The US Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.
Web Tool Helps Track or Treat Prostate Cancer
While up to half of prostate cancer cases are not life threatening, most patients choose to treat the disease with surgery or radiation. A new web-based program aims to help reduce unnecessary treatment.
Does Red Wine Fight Prostate Cancer?
You may have heard that a glass of red wine a day is good for your heart. Research now shows that the beneficial compound found in red wine may also help fight prostate cancer.
Phase I Success for new Prostate Cancer Drug
For men with aggressive prostate cancer, few treatment options are available. A new drug, however, showed a positive effect in reducing the number of tumor cells and cancer markers in advanced prostate cancer.
Early Prostate Screenings May Not Be Worth It
Prostate cancer is the most common non-skin cancer in men. While some specialty organizations recommend that screening begin at age 40, there is little evidence showing real benefits to screening at this age.
Imaging Cancer’s Return
After prostate cancer patients receive treatment, they still run the risk of the disease coming back. A newly approved imaging agent offers a way to detect recurrence earlier.